Intramedullary Osteosarcoma Treatment Market - Top Companies and Manufacturers

Companies Dominating the Intramedullary Osteosarcoma Treatment Landscape

OS Therapies
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
RefleXion
Novartis International AG
Bristol-Myers Squibb Company
Eli Lilly and Company
Pfizer Inc.
Johnson & Johnson Services, Inc.
Baxter
Aurobindo Pharma
Hikma Pharmaceuticals PLC

Browse Key Market Insights with Data Illustration:

Intramedullary Osteosarcoma Treatment Market Size & Share, Growth Forecasts 2036

In the News

October 2021 - OS Therapies, a research and clinical-stage biopharmaceutical company announced today the dosing of the "First Patient In" for its lead OST-HER2 (OST31-164) program in a potentially pivotal Phase IIb clinical trial. OST-HER2 has already received Fast-Track and Orphan Designation from the EMA and FDA. The nationwide open-label trial will enroll 39 to 45 Osteosarcoma patients whose cancer has metastasized to the lungs and has been surgically resected.
February 2023 - The U.S. Food and Drug Administration (FDA) has approved the first marketing authorization for RefleXion Medical's SCINTIXTM biology-guided radiation, a novel treatment that can be used for both early- and late-stage tumors. The CEO and co-founder of the company will be speaking live on the company's website about the groundbreaking potential of SCINTIX therapy for the treatment of cancer.

Frequently Asked Questions (FAQ)

Growing awareness regarding the disease, growing initiatives for R&D activities by governments worldwide, and a surge in technological advancements are the major factors driving the growth of the intramedullary osteosarcoma treatment market.

The market size of intramedullary osteosarcoma treatment is anticipated to attain a CAGR of 5% over the forecast period, i.e., 2024-2036.

The major players in the market are OS Therapies, RefleXion, Novartis International AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Pfizer Inc., Johnson & Johnson Services, Inc., Baxter, Aurobindo Pharma, Hikma Pharmaceuticals PLC, and others.

The hospital pharmacies segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.

Intramedullary Osteosarcoma Treatment Market - Top Companies and Manufacturers

Companies Dominating the Intramedullary Osteosarcoma Treatment Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

What are the major factors driving the growth of the intramedullary osteosarcoma treatment market?

What would be the CAGR of the intramedullary osteosarcoma treatment market over the forecast period?

Who are the major players dominating the intramedullary osteosarcoma treatment market?

Which segment captures the largest market size in the distribution channels segment in the intramedullary osteosarcoma treatment market?

Which region will provide more business opportunities for the growth of the intramedullary osteosarcoma treatment market in the future?